

## Interaction Report

Report ID:

Date Produced:

10 April 2024

## Antiretroviral Treatment

Efavirenz (EFV)  
Emtricitabine (FTC)  
Tenofovir-DF (TDF)

## Co-medications

Sildenafil (Erectile Dysfunction)  
Tadalafil (Erectile Dysfunction)  
Vardenafil (Erectile Dysfunction)

This report lists the summaries of potential interactions (i.e. "red", "amber" and "yellow" classifications) for the drugs in the table above.

Interactions with a "green" or "grey" classification (i.e. no clinically significant interaction or no clear data) have been checked and are listed at the end of this report, but summaries are not shown.

For full details of all interactions, see [www.hiv-druginteractions.org](http://www.hiv-druginteractions.org).

## Description of the interactions

Potential clinically significant interaction - likely to require additional monitoring, alteration of drug dosage or timing of administration (AMBER)

## Efavirenz (EFV) + Sildenafil (Erectile Dysfunction)

No data. Coadministration may decrease concentrations of sildenafil.

## Efavirenz (EFV) + Tadalafil (Erectile Dysfunction)

No data. Coadministration may decrease concentrations of tadalafil.

## Efavirenz (EFV) + Vardenafil (Erectile Dysfunction)

No data. Coadministration may decrease concentrations of vardenafil. Vardenafil has a possible risk of QT prolongation and/or TdP on the CredibleMeds.org website. Efavirenz was shown to prolong the QT interval above the regulatory threshold of concern in homozygous carriers of the CYP2B6\*6/\*6 allele (i.e. 516T variant in the gene encoding CYP2B6). The European product label for efavirenz contraindicates coadministration with a drug with a known risk of Torsade de Pointes whereas the American product label for efavirenz recommends that alternatives should be considered. As the potential risk of a QT interval prolongation relates specifically to homozygous carriers of CYP2B6\*6/\*6 and given the accumulated years of safety data with efavirenz and such drugs, the contraindication is not reflected in the colour coding of this interaction summary.

No clinically significant interaction expected (GREEN)

## Efavirenz (EFV) + Tenofovir-DF (TDF)

## Efavirenz (EFV) + Emtricitabine (FTC)

## Emtricitabine (FTC) + Tenofovir-DF (TDF)

## Tenofovir-DF (TDF) + Sildenafil (Erectile Dysfunction)

## Emtricitabine (FTC) + Sildenafil (Erectile Dysfunction)

## Tenofovir-DF (TDF) + Tadalafil (Erectile Dysfunction)

## Emtricitabine (FTC) + Tadalafil (Erectile Dysfunction)

## Tenofovir-DF (TDF) + Vardenafil (Erectile Dysfunction)

## Emtricitabine (FTC) + Vardenafil (Erectile Dysfunction)